SCHEMBL13696563

SCHEMBL13696563

O=C(NCC[C@@H]1[C@@H](Nc2nccc(N3CCCCCC3)n2)CCCN1C1CCCCC1)c1ccncc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 2/20 0.39
▸ HRH4 Q9H3N8 1/20 0.38
▸ BRAF P15056 1/20 0.38
▸ CCNK O75909 1/20 0.36
▸ CDK12 Q9NYV4 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ JAK2 O60674 5/20 0.36
▸ JAK1 P23458 5/20 0.36
▸ TYK2 P29597 5/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ RAF1 P04049 1/20 0.36
▸ HSPB1 P04792 1/20 0.36
▸ LYN P07948 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ MRGPRX1 Q96LB2 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35
▸ DPP4 P27487 1/20 0.35
▸ PREP P48147 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2037748 1.00 CXCR4 (0.39) CXCR4HRH4BRAFCCNKCDK12
SCHEMBL4116141 0.92 CXCR4 (0.40) CXCR4HRH4CCNKCDK12JAK2
SCHEMBL2011688 0.90 ALDH1A1 (0.40) CXCR4JAK3DPP4PREPFAP
SCHEMBL13696562 0.90 ALDH1A1 (0.40) CXCR4JAK3DPP4PREPFAP
SCHEMBL4116420 0.89 CXCR4 (0.43) CXCR4HRH4CCNKCDK12MRGPRX1
SCHEMBL4116308 0.88 HRH4 (0.42) CXCR4HRH4CCNKCDK12JAK2
SCHEMBL13696561 0.87 CXCR4 (0.43) CXCR4KDM4EHSD11B1
SCHEMBL4116233 0.87 CXCR4 (0.43) CXCR4KDM4EHSD11B1
SCHEMBL13696571 0.85 HRH4 (0.40) CXCR4HRH4CCNKCDK12
SCHEMBL13696552 0.84 CXCR4 (0.44) CXCR4HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed
EP-1852432-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 CXCR4 1/4885HRH4 152/4885BRAF 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback